ImmunityBio Inc. Reports Strong Long‑Term Outcomes for Bladder Cancer Therapy

ImmunityBio Inc. (NASDAQ: IMMUN) announced the release of Phase 3 clinical data for its bladder‑cancer product ANKTIVA® Plus BCG. The study, conducted in patients with BCG‑unresponsive non‑muscle‑invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) and optionally papillary tumors, demonstrated an 84 % cystectomy‑avoidance rate at three years. In addition, a subset of patients achieved complete responses that persisted beyond 53 months.

Key Findings

  • Cystectomy Avoidance: 84 % of participants avoided radical cystectomy over a three‑year follow‑up.
  • Durable Responses: Complete responses were maintained beyond 53 months in a proportion of patients.
  • Safety Profile: The safety data remained consistent with prior analyses, with no new safety signals identified.

The data were presented on 16 October 2026 and received positive coverage in multiple financial news outlets, including investing.com, ceo.ca, and de.investing.com.

Regulatory Milestones

On 15 October 2026, ImmunityBio received an expansion of its U.S. label for ANKTIVA. The U.S. Food and Drug Administration (FDA) extended the indication to cover BCG‑unresponsive NMIBC with CIS, with or without papillary tumors. The expansion follows the Phase 3 results and supports a broader patient population.

Financial analysts reiterated their positive outlook on the stock. H.C. Wainwright maintained a strong rating for ImmunityBio following the FDA approval, citing the expanded market access and robust clinical evidence.

Market Context

The broader checkpoint inhibitor refractory cancer market is projected to grow to USD 133.96 billion by 2035, according to Credence Research. The market is expected to expand at a compound annual growth rate of 12.13 % from 2025 to 2035. North America currently holds the largest regional share (47 %) while Asia Pacific is projected to experience the fastest growth (13.77 % CAGR). ImmunityBio’s ANKTIVA operates within this expanding therapeutic space, targeting a subset of patients that remain underserved by existing therapies.

Company Background

ImmunityBio specializes in cell and immunotherapy products for a range of diseases, including cancers, infectious, and inflammatory conditions. The company is headquartered in Culver City, United States, and trades on the Nasdaq. As of 15 October 2026, its market capitalization stands at USD 10.6 billion, with a closing price of USD 9.18. The company’s 52‑week trading range spans USD 1.95 to USD 12.43.

The recent data release and regulatory approval reinforce ImmunityBio’s position as a key player in the oncology immunotherapy landscape, potentially enhancing its valuation and investor appeal as the market for checkpoint‑inhibitor‑refractory therapies continues to expand.